Trial Profile

Safety and pharmacokinetic study of sacubitril/valsartan (LCZ696) and atorvastatin in healthy Chinese male subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Jun 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sacubitril/valsartan (Primary) ; Atorvastatin
Indications Essential hypertension; Heart failure; Hypertension
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

10 Jun 2016 New trial record
31 May 2016 Results published in the European Journal of Drug Metabolism and Pharmacokinetics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com